VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2015 | Results of the phase 2 trial of daratumumab in multiple myeloma

Joseph Mikhael • 2 Jun 2015
ASCO 2015
Multiple Myeloma Daratumumab

Dr Joseph Mikhael, at ASCO 2015, discusses the results of the phase 2 study of daratumumab in patients with 3 or more lines of prior therapy, or double refractory multiple myeloma.

More from Joseph Mikhael

1:53
The future of multiple myeloma treatment
Joseph Mikhael • 21 Oct 2020
2:10
Mentorship in the virtual era
Joseph Mikhael • 21 Oct 2020
3:08
Disparities between African American and Caucasian patients with MM
Joseph Mikhael • 21 Oct 2020
2:12
Social media – a useful tool for hematological research
Joseph Mikhael • 22 Jun 2017

Related Videos

1:06
Updates from the LocoMMotion study
Hermann Einsele • 11 Jun 2022
1:43
Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma
Hermann Einsele • 11 Jun 2022
2:12
Safety and efficacy of REGN5458 in patients with relapsed/refractory (R/R) multiple myeloma
Joshua Richter • 11 Jun 2022
1:07
Updated results from CARTITUDE-1
Yi Lin • 11 Jun 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals